ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Gut microbiota in treatment-naïve active Crohn's disease compared to those in remission: Divergent trends in mucosal versus fecal bacterial community.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
objectivesEvaluating the gut microbial community in Crohn's disease (CD) is best done before commencing therapy to avoid the effects of therapeutic intervention and provide a better understanding of microbial dysbiosis. We compared the microbial communities in both tissue and stool samples from treatment-naive CD patients with those in remission.
methodsAdults with CD were prospectively recruited. Patients with Crohn's disease activity index (CDAI) > 150 and no prior therapy were included as treatment-naive active cases and those with CDAI ≤ 150 were considered to be in remission. Stool and rectal mucosal biopsy samples were collected, bacterial DNA was extracted, the V3-V4 region of the 16S rRNA gene was amplified and library preparation was done and sequenced on the Illumina MiSeq platform. The microbial community composition, diversity and predicted function were assessed using the QIIME2 pipeline and R packages. Microbial characteristics associated with disease status were determined.
resultsThirty-four active CD cases (age 40.9 ± 11.2 years, males 61.8%) and 33 in remission (age 39.5 ± 10.2 years, 60.6% males) were recruited. Changes in bacterial diversity with disease status were more pronounced in stool than in tissue samples. On random forest analysis of the stool sample, genera such as Romboutsia, Ruminococcus and Dorea were associated with active CD, while Bifidobacterium, Escherichia and Enterococcus were associated with remission. In the mucosal sample, Bacillus, Megasphaera and other species were associated with active CD, while Veillonella, Fusobacterium, Bifidobacterium and other species were associated with remission. Several predicted metabolic pathways showed significant differences between the mucosal bacteria of active CD and those in remission. This difference was less pronounced between the two groups' stool samples.
conclusionThe microbial community structure and predicted function in treatment-naïve CD differ from those in remission. The predicted differences at the functional level are prominent in the mucosal microbiota, which are not replicated in the fecal community.
Indexed as
Identifiers
42334790What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.